Physician profile
Randi Berg
NPI 1578008769
$1,791.54
in general payments reported to CMS, 2019-2025
23 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.19 · 2022: $512 · 2023: $604 · 2024: $236 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.08 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $438.29 | 2022-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $202.00 | 2022-2025 | Trelegy Ellipta, Shingrix, Penmenvy |
| Lilly USA, LLC | $182.77 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $177.87 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.99 | 2021-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $101.12 | 2022-2023 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $84.08 | 2023-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $60.52 | 2022-2023 | |
| Abbott Laboratories | $45.57 | 2022-2023 | Freestyle Libre 2 |
| Exact Sciences Corporation | $44.79 | 2024-2025 | Cologuard Collection Kit |
| Organon LLC | $44.18 | 2022 | |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $31.53 | 2023 | |
| Harmony Biosciences LLC | $29.96 | 2024 | |
| Pfizer INC. | $29.54 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $25.06 | 2022 | |
| Mylan Specialty L.P. | $23.20 | 2023 | Yupelri |
| Astellas Pharma US INC | $22.54 | 2023 | Myrbetriq |
| Viatris Specialty LLC | $17.43 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $17.41 | 2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $16.30 | 2022 | |
| Scilex Pharmaceuticals INC. | $14.32 | 2023 | Ztlido |
| Sanofi-Aventis U.S. LLC | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.